Positron emission tomography (PET) with 2-[18F]fluoro-2- deoxy-D-glucose (FDG) is a noninvasive imaging technique that provides a fundamental advantage by allowing the functional characterization of lymphoma tissue via the detection of increased glycolysis, which is a typical sign for an active tumor. Whole-body FDG-PET generates tomographic images of the entire patient and shows the distribution of FDG throughout the body. There is growing evidence that FDG-PET is more accurate in the staging of lymphoma patients compared with conventional staging procedures. Several investigators have shown the potential of FDG-PET in the nodal staging, in the detection of extranodal lymphoma, as well as for bone marrow involvement. In lymphoma patients with residual masses after treatment, a negative PET result was associated with a high chance of complete remission. A whole-body FDG-PET-based staging and follow-up algorithm may be an accurate and cost-effective method for monitoring lymphoma. In the future, immunoscintigraphic studies using FDG-PET with radiolabeled monoclonal antibodies and studies on the pharmacokinetics of cytostatic will follow, especially on the background of future treatments, such as gene therapy.

This content is only available via PDF.
© 1999 S. Karger GmbH, Freiburg
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.